Skip to main content
Zelluna ASA logo

Zelluna ASA — Investor Relations & Filings

Ticker · ULTI ISIN · NO0010851603 LEI · 254900B4VALJZR9TL744 OL Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2024-06-01 Report Publication Anno…
Country NO Norway
Listing OL ULTI

About Zelluna ASA

https://www.zelluna.com/

Zelluna ASA is a cell therapy company pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company's proprietary TCR-NK platform is designed to combine the high-precision targeting of TCRs with the potent, innate anti-tumor activity of NK cells. This approach aims to overcome the challenges associated with treating solid tumors. Zelluna is focused on creating a new generation of allogeneic, "off-the-shelf" cell therapies. The mission is to deliver transformative and potentially curative treatments for patients with advanced solid cancers, addressing a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Report Publication Announcement Classification · 99% confidence The document is a 'NON-REGULATORY PRESS RELEASE' announcing that data from a clinical trial (INITIUM) will be presented as a poster at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. It details the abstract number, session title, date, and time of the presentation. This is not a full financial report (like 10-K or IR), nor is it a formal regulatory filing like a DVA or DIRS. Since it is an announcement about the presentation of scientific/clinical data, and it is a press release, it fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous, non-core financial announcement, or potentially as a general Investor Presentation (IP) announcement, but RNS is the safer fallback for general press releases about corporate activities that don't fit specific financial/governance codes. Given the context of clinical data presentation, RNS is appropriate as a general corporate update/announcement.
2024-06-01 English
Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update
Earnings Release Classification · 99% confidence The document is titled "First Quarter 2024 Business Update and Financial Results" and contains detailed slides covering clinical updates (Phase II program status, trial readouts like FOCUS Q3 2024, DOVACC H1 2025), regulatory designations, and a specific 'Financial update' section detailing Q1 2024 Key Financials, cash position, and cash runway extension due to operational adjustments. This structure—a comprehensive review of operational, clinical, and financial performance for a specific fiscal period (Q1 2024)—is characteristic of an Investor Presentation (IP) or a detailed Interim/Quarterly Report (IR). Since it is presented as a slide deck ('This presentation has been prepared...') detailing results and strategy updates, Investor Presentation (IP) is the most fitting category, as it often accompanies or precedes the formal Interim Report (IR). Given the depth of clinical trial status and financial highlights presented in a presentation format, IP is selected over the more formal IR. Q1 2024
2024-05-07 English
Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive 'First Quarter 2024 Business Update' for Ultimovacs ASA. It contains detailed financial statements (balance sheet/income statement data), management's discussion and analysis of clinical trial results (INITIUM, NIPU, etc.), and operational updates. It is not merely an announcement of a report, but the report itself, containing substantive financial data and analysis for the Q1 2024 period. Therefore, it is classified as an Interim/Quarterly Report. Q1 2024
2024-05-07 English
Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update
Earnings Release Classification · 100% confidence The document explicitly states in the title and opening paragraph: "Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update". It details financial figures for Q1 2024 (operating expenses, net negative cash flow, cash position as of March 31, 2024) and provides a business update including clinical trial progress. This content aligns perfectly with the definition of an Interim / Quarterly Report (IR). Although it mentions a conference call and webcast, the document itself contains the detailed financial and operational results, making it the report, not just an announcement of the report's publication (RPA). Since it covers a period shorter than a year (First Quarter), 'IR' is the most appropriate classification over '10-K'. Q1 2024
2024-05-07 English
Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation
Report Publication Announcement Classification · 99% confidence The document is titled 'Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation'. It explicitly invites stakeholders to a webcast presentation for the first quarter 2024 results and states that 'The report and presentation will be available on the company website from 07:00 CET the same day.' Since the document is an invitation/announcement about the upcoming release of the Q1 results and presentation, and not the results themselves, it fits the definition of a Report Publication Announcement (RPA). The document length (1233 chars) is very short, supporting the 'MENU VS MEAL' rule.
2024-04-30 English
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Report Publication Announcement Classification · 99% confidence The document is titled "Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting" and details the abstract number, session title, date, and time of a scientific presentation. This is an announcement about the presentation of clinical trial data, not the full financial report (10-K, IR) or the presentation itself (IP). Since it is a specific announcement regarding company activity (clinical data presentation) that doesn't fit the other specific categories like ER, DIV, or MANG, it falls best under the general Regulatory Filings category (RNS) as a non-regulatory press release detailing corporate/clinical updates, or potentially a general Investor Relations announcement. Given the options, RNS serves as the best general regulatory/corporate announcement fallback for specific, non-financial updates like conference presentations.
2024-04-24 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.